Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 15/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 15/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8420623 | 0.90 | LTB4R (0.68) | LTB4RLTB4R2PPARGPTGESALOX5 | |
| SCHEMBL8420622 | 0.90 | LTB4R (0.68) | LTB4RLTB4R2PPARGPTGESALOX5 | |
| SCHEMBL7988072 | 0.83 | LTB4R (0.82) | LTB4RLTB4R2 | |
| SCHEMBL7990289 | 0.79 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL7990284 | 0.79 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL7989763 | 0.79 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL8599326 | 0.77 | LTB4R (0.69) | LTB4RLTB4R2ABCB1 | |
| SCHEMBL8570246 | 0.77 | LTB4R (0.69) | LTB4RLTB4R2ABCB1 | |
| SCHEMBL8560587 | 0.77 | LTB4R (0.57) | LTB4RLTB4R2 | |
| SCHEMBL8420340 | 0.76 | LTB4R (0.59) | LTB4RLTB4R2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |